

**Effect of Ranolazine and Dronedarone on
Isoproterenol induced cardiac dysfunction in rats**

Thesis

**Submitted in partial fulfillment of the requirements for the degree MSc
in pharmacology**

By

Samar Nageeb Ahmed

M.B., B.Ch.

Demonstrator of pharmacology
Faculty of medicine Fayoum University

Supervised by

Dr. Sawsan Abd El-Aziz Sadik

Professor of pharmacology
Faculty of medicine Fayoum University

Dr. Nawal El- Sayed El-Gawhary

Professor of pharmacology
Faculty of medicine Cairo University

Dr. Eman Ibrahim Ahmed

Lecturer of pharmacology
Faculty of medicine Fayoum University

Department of pharmacology

Faculty of medicine

Fayoum University

2015

ABSTRACT

The present study demonstrates the effect of ranolazine (an inhibitor of the late sodium current) and dronedarone (a potassium channel blocker) on cardiovascular dysfunction in isoproterenol induced cardiotoxicity in rats.

Ranolazine (20 mg/kg), dronedarone (30mg/kg) were administered orally once daily for 14 days and isoproterenol (85mg/kg) was injected subcutaneously once on the day 13 and 14 to study their effects on electrocardiogram changes (heart rate, QT and QTc intervals), oxidative stress parameters (serum malondialdehyde and serum super oxide dismutase) and histopathological analysis of cardiac tissue.

The results of the present study showed that dronedarone significantly decreased heart rate by 17%, QT interval by 10% and QTc interval by 15% after isoproterenol injection. On the other hand there was no significant difference regarding heart rate, QT and QTc intervals in ranolazine group compared to isoproterenol.

Ranolazine and dronedarone significantly decreased serum malondialdehyde by 38% and significantly increased serum superoxide dismutase by 60% after isoproterenol injection. The histopathological examination by the light microscopy using Hematoxylin and Eosin revealed that ranolazine and dronedarone decreased cardiac inflammation and vacuolation to the same extent.

The results of the present work implicate that short term treatment with ranolazine and dronedarone may produce a therapeutic potential for treating isoproterenol induced cardiovascular dysfunction.

Key Words: Cardiotoxicity, Isoproterenol, Ranolazine, Dronedarone